Clinical trial · Observational
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Company Decision
Summary
Brief summary (as posted)
This natural history study is a prospective and retrospective, observational study of WHIM patients. WHIM syndrome is a rare, genetic, primary immunodeficiency disorder (a disorder in which the body's immune system does not function properly). WHIM is an acronym for some of the symptoms of the disorder - Warts, Hypogammaglobulinemia (low levels of certain antibodies), Infections and Myelokathexis (too many white blood cells in the bone marrow).This study includes 10-year retrospective (Retrospective Phase) and up to 5-year prospective (Prospective Phase) components.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| WHIM Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (13)
- measure
- Incidence of infections
- timeFrame
- Up to five years, from time of enrollment through study completion or early termination
- description
- Infections assessed by hospitalizations (including intensive care), antibiotic use, outpatient medical appointments and missed days of school/work.
- measure
- Severity of infections
- timeFrame
- Up to five years, from time of enrollment through study completion or early termination
- measure
- Incidence of warts
- timeFrame
- Up to five years, from time of enrollment through study completion or early termination
- measure
- Severity of warts
- timeFrame
- Up to five years, from time of enrollment through study completion or early termination
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Has a confirmed clinical diagnosis of WHIM syndrome. 2. Has signed the current approved informed consent form; patients under 18 years of age will sign an approved informed assent form and must also have a signed parental consent. 3. Be willing and able to comply with the study protocol. Exclusion Criteria: 1. Has, within 6 months prior to Day 1, received a CXCR4 antagonist. 2. Currently participating in an investigational study for treatment of WHIM. 3. Has any other medical or personal condition that, in the opinion of the Investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical study.
References
Publications (0)
Data not yet available